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Abstract
Butyrylcholinesterase (BChE) is a plasma enzyme that catalyzes the hydrolysis of choline esters, including the mus-
cle-relaxant succinylcholine and mivacurium. Patients who present sustained neuromuscular blockade after using
succinylcholine usually carry BChE variants with reduced enzyme activity or an acquired BChE deficiency. We report
here the molecular basis of the BCHE gene underlying the slow catabolism of succinylcholine in a patient who under-
went endoscopic nasal surgery. We measured the enzyme activity of BChE and extracted genomic DNA in order to
study the promoter region and all exons of the BCHE gene of the patient, her parents and siblings. PCR products
were sequenced and compared with reference sequences from GenBank. We detected that the patient and one of
her brothers have two homozygous mutations: nt1615 GCA > ACA (Ala539Thr), responsible for the K variant, and
nt209 GAT > GGT (Asp70Gly), which produces the atypical variant A. Her parents and two of her brothers were
found to be heterozygous for the AK allele, and another brother is homozygous for the normal allele. Sequence anal-
ysis of exon 1 including 5'UTR showed that the proband and her brother are homozygous for -116GG. The AK/AK
genotype is considered the most frequent in hereditary hypocholinesterasemia (44%). This work demonstrates the
importance of defining the phenotype and genotype of the BCHE gene in patients who are subjected to
neuromuscular block by succinylcholine, because of the risk of prolonged neuromuscular paralysis.
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Butyrylcholinesterase or pseudocholinesterase is a
serine hydrolase that catalyses the hydrolysis of choline es-
ters, including the muscle-relaxant succinylcholine and mi-
vacurium. Currently, succinylcholine is the drug of choice
for tracheal intubation in rapid-sequence inductions, as in
emergency situations, and for patients at high risk of gastro-
esophageal reflux (Caldwell, 2004; Miller, 2004).
After the introduction, in 1951, of suxamethonium
chloride as a muscle relaxant drug, it was noticed that sub-
jects with butyrylcholinesterase deficiency to which this
drug was given suffered from prolonged neuromuscular
blockade, requiring continuous artificial respiratory sup-
port (Evans et al., 1952). Later on, BChE deficiency was
identified as an inherited condition in which the plasma en-
zyme was unable to hydrolyze the drug efficiently that
could be identified and classified by biochemical analysis
(Kalow and Genest, 1957).
The phenotypic classification of BChE is made by
measuring the enzyme activity and by using specific en-
zyme inhibitors that produce phenotype-specific patterns of
`inhibitor numbers'. The silent phenotype is characterized
by the complete absence of BChE activity or by an enzyme
activity < 10% of the average levels of the usual phenotype.
The atypical (A) variant resists in vitro to the inhibition by
dibucaine. The K variant (named in honor of Dr. Werner
Kalow) is associated with a reduction in BChE activity
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(Rubinstein et al., 1978), and is a variant that can only be
identified by inhibition methods when it occurs in hetero-
zygosis with the atypical variant allele (Goodall, 2004), al-
though sometimes the phenotype classification may not
correspond to the DNA analysis (Bartels et al., 1992).
Recently, DNA sequencing has made it possible to
identify the BChE variants at the DNA level. It was demon-
strated that the alleles BCHE*A and BCHE*K correspond,
respectively, to the point mutations nt209 GAT > GGT
(Asp70Gly) and nt1615 GCA > ACA (Ala539Thr),
whereas different mutations have been described as being
responsible for the silent phenotype (La Du et al., 1990;
Bartels et al., 1992; Lockridge and Masson, 2000;
Parmo-Folloni et al., 2008).
A mutation detection approach has already been pro-
posed for the investigation and characterization of the
BChE variants in individuals who present reduced plas-
matic enzyme activity and need to undergo anesthetic pro-
cedures. What makes this approach advantageous is the fact
that the phenotype is well defined, the gene is relatively
small (73 kb; four exons interrupted by 3 introns with exon
1 not translated; coding region 1722 nucleotides), and the
majority of abnormalities described are point mutations
(Yen et al., 2003; Goodall, 2004).
In this study, we report the mutations in the BCHE
gene responsible for the prolonged neuromuscular block-
ade presented by a patient subjected to an endoscopic nasal
surgery at the Hospital das Clínicas, Faculdade de Me-
dicina de Ribeirão Preto, USP, Ribeirão Preto, SP, Brazil.
Afterwards, other members of the family were screened for
the same mutation.
The patient, a woman, was 34 years old at the time of
the study, weighed 90 kg, had untreated chronic arterial hy-
pertension, presented recurring epistaxis for 24 h and was
hospitalized in the Otolaryngology Department for etiolog-
ical investigation. Nasal fibroscopy was performed, which
showed active bleeding in the right sphenopalatine artery
area. Homeostasis was tried with a nasal tampon. After two
days, as the patient's bleeding continued, an endoscopic li-
gation of the sphenopalatine artery was performed, under
general anesthesia, with an estimated duration of 30 to
60 min.
As preanesthetic medication 1.5 mg midazolam were
used, and the patient was monitored with a pulse oximeter,
electrocardiogram and an automatic noninvasive blood
pressure monitor. Anesthesia was induced with remi-
fentanil in continuous infusion, etomidate (0.2 mg/kg),
suxamethonium (1.1 mg/kg) and, after the orotracheal intu-
bation, atracurium (0.4 mg/kg). The anesthesia was main-
tained with continuous administration of propofol and
remifentanil.
Although the patient had been fasting for over eight
hours, rapid-sequence orotracheal intubation was chosen
due to the presence of blood in the airways. The surgical
procedure lasted 55 min and was accomplished without
complications. Immediate drug suspension at the infusion
pump and neuromuscular block reversion with atropine
(1 mg) and neostigmine (2 mg, plus 1 mg) were done.
Fifteen minutes after the end of the procedure, the pa-
tient presented tachycardia, lacrimation and lack of motor
muscular response. Due to the prolonged neuromuscular
block, the patient was sedated and monitored with TOF
(train of four, TOF-Guard INMT®). After succinylcholine
administration, the first response in TOF appeared in
155 min, and spontaneous ventilation in 250 min. At this
time, TOF was 40%. After 355 min, the patient had three
consecutive TOF measurements over 90%. Sedation was
discontinued, the airways were aspirated, and the patient
extubated.
Due to the symptoms presented, the possibility of the
patient having butyrylcholinesterase deficiency was raised.
Plasma cholinesterase measured by the photocolorimeter
method was 1,310 U/L (normal reference rate: 3,200 to
9,000 U/L) (Table 1). After the initial evaluation, it was
suggested to continue the investigation through enzyme ac-
tivity measurements and molecular biology studies of the
patient and her family. They all signed informed consent
forms for genetic studies.
Before the molecular analysis, butyrylcholinesterase
enzyme activity was measured in the samples obtained, us-
ing the method described by Garry and Routh (1965). This
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Table 1 - BChE enzyme dosage and activity in the patient (II.2) and her relatives.
Subject Age (years) Enzyme dosage (U/L) quantitative Enzyme activity dosage (MSH/3 min/mL) qualitative Genotype
I - 1 62 3323 14.15 UU/AK
I - 2 58 2924 13.67 UU/AK
II - 1 39 np 2.42 AK/AK
II - 2 34 1310 0.264 AK/AK
II - 3 31 2924 24.8 UU/AK
II - 4 21 np 37.2 UU/AK
II - 5 20 np 46.6 UU/UU
np: not performed.
is a colorimetric method for plasma or serum, using acetyl-
thiocholine as substrate and 2 nitrobenzoic acid (5:5-di-
thiobis) (DTNB) as chromogenic agent. Plasma
cholinesterase acts on acetylthiocholine releasing thiocho-
line which reacts with DTNB, producing a yellow color.
The enzyme activity is measured after incubation for 3 min
at 37 °C, and then the reaction is stopped by adding quini-
dine sulfate. The difference in absorbance between the test
and the blank is measured at 412 nm in a spectropho-
tometer.
Genomic DNA was extracted from peripheral blood
leukocytes, using a Super Quick-gene-rapid DNA isolation
kit (Promega), following the manufacturer's instructions.
The BCHE promoter region and its four exons were
amplified by PCR using specific primers as described by
Levano et al. (2005) (Table 2).
All PCR reactions were standardized with the follow-
ing conditions: 2.5 mM of each primer, 2.5 mM of dNTPs,
2.5 L of 1x buffer (Biotools), 1U of Taq polymerase
(Biotools); 200 ng of genomic DNA, and 14 L of distilled
water, in a final reaction volume of 25 L. PCR was per-
formed as follows: an initial denaturation step of 4 min, fol-
lowed by 35 cycles consisting of 40 s at 94 °C (denatur-
ation), 50 s at annealing temperatures (specific for each
reaction) (Table 2), an extension of 50 s at 72 °C, and a final
extension of 10 min at 72 °C.
The PCR-amplified DNA fragments were subjected to
direct sequencing in an automatic capillary sequencing system
(MegaBACE 1000 DNA Sequencing System®, Molecular
Dynamics & Amersham Life Science), using a DYEnamic
ET terminator Sequencing System® kit and the same PCR
primers, following the manufacturer's instructions.
The sequencing results were analyzed using the
FinchTV version 1.4.0 (Geospiza Inc. 2004-2006) and
Polyphred (Geospiza Inc.) softwares; the sequences ob-
tained were compared with reference sequences from
GenBank (NM_000055). The nomenclature used to
classify the genotypes was as proposed by La Du et al
(1991).
The BChE enzyme activity measurements (expressed
in M SH/3 min/mL of plasma) of the patient, her parents
and her siblings, are presented in Table 1.
The molecular analyses revealed that the proband
(II.2) and her brother (II.1), who has low enzyme activity
too, present two point mutations in homozygosis: nt1615
GCA > ACA (Ala539Thr), responsible for the K variant,
and nt209 GAT > GGT (Asp70Gly), which produces the
atypical variant. Her parents (I.1 e I.2), as well as two of her
siblings (II.3 e II.4), are heterozygotes for these two sites of
the BCHE gene, and her other brother (II.5), who presented
the highest enzyme activity, is homozygous for the usual
(normal) variants at both examined sites (Figures 1 and 2).
The analysis of exon 1 including 5'UTR showed that the
proband and her brother with low enzyme activity (II.1) are
both homozygous for -116G.
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Figure 1 - Pedigree of the studied family.
Table 2 - Primers used for amplification and sequencing of the promoter and coding regions of the BCHE gene.
Primer names Primer sequences Size of the PCR products (bp) Annealing temperature (°C)
BCHEPF GTATGACTTAAATAAGTGTTG 521 52
BCHEPR GAATGTAACAATCAACTGTTAC
BCHEEx1F AACAGATTTCAAGTTGCTGCTG 261 57
BCHEEx1R TCATCCCACAGAATGAGCTTT
BCHEEx2F1 TCTTTTGCTCTGCATGCTTATTG 450 59
BCHEEx2R1 CTTTCAACCCGAGCCAGAAA
BCHEEx2F2 TGGATTCCAGCACCTAAACC 624 58
BCHEEx2R2 TATGTCTGGCATGTCAGTGAGA
BCHEEx2F3 AACTTTGGTCCGACCGTGGAT 618 61
BCHEEx2R3 AAAACGGATCAAACCAAGCCAG
BCHEEx3F AGCCCAGTTCACATACGTT 407 55
BCHEEx3R CACCGTGCCTTGGAGAGTAT
BCHEEx4F AAAATGGCTTTTGTATTCGAAATTA 750 57
BCHEEx4R GTGGCTGAGCCTCTCATTTT
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Figure 2 - Description of the mutations in the BCHE gene of the patient and her relatives. The figure shows the sequencing electropherograms of the am-
plified fragment of exons 2 and 4 of the analyzed individuals. The highlighted bases (blue) indicate the position of the mutations. The left column shows
the results of the analysis of exon 2. Missense mutation GAT to GGT in codon 70 was found in heterozygosis in subjects I-1, I-2, II-3 and II-4, and in
homozygosis in subjects II-1 and II-2 (patient). The right column shows the results of the analysis of exon 4. Missense mutation GCA to ACA in codon
539 was found in heterozygosis in individuals I-1, I-2, II-3 and II-4, and in homozygosis in individuals II-1 and II-2 (patient). Subject II-5 did not present
mutations in any of both exons. Individuals are identified as in Figure 1.
Prolonged neuromuscular blockade after the use of
succinylcholine occurs in patients with a significant BChE
deficiency, compromising more than 70% of the enzyme
activity, and is caused mostly by genetic abnormalities.
Hypocholinesterasemia may also occur during pregnancy,
liver diseases, malnutrition and chronic diseases, but in
these cases the enzyme deficiency is usually low, and there
is rarely a prolonged neuromuscular blockade (about 6% of
the cases) (Viby-Mogensen and Hanel, 1978).
Variant K presents a linkage disequilibrium regarding
the point mutation responsible for the atypical variant in
89% of its carriers (Bartels et al., 1992). This association
contributes to the additional 33% reduction in the BChE en-
zyme activity Vmax in atypical (A) serum. Patients with ge-
notype AK/AK have reduced enzyme activity, and this is the
most common genotype responsible for hereditary hypo-
cholinesterasemia (44%) (Yen et al., 2003). Furtado-Alle et
al. (2008) found that point mutation -116G > A in exon 1 of
the BCHE gene in cis with the K variant is also responsible
for the decrease in BChE activity.
In the case reported here, the prolonged neuromus-
cular blockade after use of succinylcholine was due to the
association of variants A and K in cis (genotype AK/AK), as
described by Yen et al (2003), and not to the association of
variants K and -116A in cis. We also showed the importance
of knowing the BChE phenotype and genotype of patients
who will undergo surgical procedures when the use of
succinylcholine or mivacurium is indicated as a neuromus-
cular blocker drug. The risk of prolonged neuromuscular
blockade in these cases is estimated at 2.18% (Vaisi-Ray-
gani et al., 2007).
This study makes it clear that, whenever a subject
with butyrylcholinesterase deficiency is detected, the pa-
tient's family, especially his/her siblings, should be investi-
gated, because, although the enzyme activity is determined
in a codominant manner, the clinical phenotype usually dis-
plays a recessive pattern.
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